Physician profile
David Benjamin Askin
NPI 1043424542
$1,031.26
in general payments reported to CMS, 2019-2025
15 companies · $41.20 in 2025
The $41.20 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $410 · 2022: $447 · 2023: $133 · 2025: $41.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $174.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $173.97 | 2022 | |
| Kite Pharma, INC. | $127.67 | 2021-2023 | |
| Global Blood Therapeutics, INC. | $125.69 | 2021-2022 | |
| Celgene Corporation | $121.30 | 2022 | |
| Rigel Pharmaceuticals, INC. | $115.73 | 2021 | |
| Seagen INC. | $99.95 | 2021 | |
| Pfizer INC. | $44.20 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $43.35 | 2021 | |
| Jazz Pharmaceuticals INC. | $41.20 | 2025 | |
| Astellas Pharma US INC | $38.97 | 2023 | Xospata |
| Sobi, INC | $32.84 | 2022-2023 | |
| Cti Biopharma Corp. | $24.93 | 2023 | Vonjo |
| Sirtex Medical INC | $15.94 | 2022 | |
| Veracyte, INC. | $13.02 | 2022 | |
| Emd Serono, INC. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Askin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.